Phase I trial of epirubicin and taxotere [docetaxel] in patients with metastatic androgen independent prostate cancer

Trial Profile

Phase I trial of epirubicin and taxotere [docetaxel] in patients with metastatic androgen independent prostate cancer

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Dec 2008

At a glance

  • Drugs Docetaxel (Primary) ; Epirubicin (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 04 Dec 2008 Status changed from suspended to completed, according to clinicaltrials.gov.
    • 16 Apr 2008 The lead investigated has changed from Chaudhary UB to Kraft AS according to clinicaltrials.gov.
    • 02 Jan 2008 Status changed from recruiting to suspended.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top